Eli Lilly Medications

Eli Lilly’s Full-Year Profit Views in Line

Hosted on MSN · 1h

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Reuters · 3h

Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.

Associated Press · 24m

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.

1hon MSN

Eli Lilly reports mixed earnings, increases 2025 guidance

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...

1hon MSN

Lilly says Mounjaro and Zepbound contributed to big revenue boost

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

1don MSN

Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results